Status:
COMPLETED
Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects
Lead Sponsor:
Bayer
Conditions:
Healthy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine what effect Magnevist (gadopentetate dimeglumine) injection has on the way the heart conducts the electrical impulses that allow it to beat effectively. The s...
Detailed Description
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Subjects with an electrocardiogram \[ECG\] (normal sinus rhythm \[SR\], QTc \> 450 msec) without clinically significant abnormalities
- Non-smoker
Exclusion
- History of cardiovascular disease- Pregnant or nursing- Had any contraindication to moxifloxacin
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2004
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00310596
Start Date
January 1 2004
End Date
March 1 2004
Last Update
December 30 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Miami, Florida, United States, 33181-3405